We are pleased to release our review of M&A, private equity and venture capital activity across the UK healthcare sector in Q3 of 2024.
Our report, which can be downloaded below, highlights the most active sub-sectors, along with a month-by-month summary of the key deals across the market.
Q3 2024 Healthcare M&A Review Summary
Deal Volumes
Deal activity across Q3 of 2024 has remained at consistent levels, without showing any notable increases on the first half of the year
Activity is expected to peak in October as vendors look to complete deals prior to potential capital gains tax changes announced in the Autumn Budget
Aside from any short-term volatility as a result of the Budget on 30 October, strong underlying drivers in the healthcare market will continue to drive deal activity
Sub-sector Activity
Medical equipment was the most prolific area of the market in Q3, with deals covering mobility products, single use devices and diagnostic equipment
Strong clinical services activity was focused on private pay outpatient and community-based services, in addition to neurodiversity and mental health services
Digital health deals were centred around electronic patient records and e-learning
Private Equity Involvement
Private equity activity remained positive in the quarter, with over 50% of transactions involving private equity either through direct investment or via bolt-on deals
The period saw new platforms for Panoramic (Millercare), Sullivan Street (UKAT), Palatine (The Mole Clinic), CVC DIF (Medneo UK), Rockpool (Oxford Online Pharmacy), Lexxic (Agathos), LDC (Medray), NorthEdge (Latus) and Duke Street (AGITO)
Commentaires